Skip to main content
Premium Trial:

Request an Annual Quote

Invitrogen's Acquisition of ABI Topped Most-Read GenomeWeb Daily News Articles from Last Week

NEW YORK (GenomeWeb News) - What are GenomeWeb Daily News subscribers reading? Below are the five most-read articles for the five-day period ended Friday, June 13.
 
1. Invitrogen to Acquire Applied Biosystems for $6.7B (from June 12)
 
2. Tony White to Consult for Merged Invitrogen, Applied Biosystems (from June 13)
 
3. Hologic to Acquire Third Wave for $580M (from June 9)
 
4. Lucier Brushes Off Integration Worries in Merger with ABI (from June 13)
 
5. 454, ABI, Illumina Lend 1000 Genomes Project More Sequencing Muscle (from June 11)
The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.